Literature DB >> 21255571

The tumor suppressor RECK interferes with HER-2/Neu dimerization and attenuates its oncogenic signaling.

Kun-Jing Hong1, Ming-Chuan Hsu, Ming-Fen Hou, Wen-Chun Hung.   

Abstract

Our previous study demonstrates that HER-2/Neu oncogene inhibits a matrix metalloproteinase inhibitor and tumor metastasis suppressor RECK to promote metastasis. Conversely, the effect of RECK on the oncogenic function of HER-2/Neu is unknown. Ectopic expression of RECK in 293T cells and HER-2/Neu-overexpressing breast cancer cells shows that RECK and HER-2/Neu are co-localized and these two proteins can be co-immunoprecipitated. RECK inhibits HER-2/Neu receptor dimerization and autophosphorylation, which causes reduction of ERK and AKT kinase activity and down-regulation of HER-2/Neu target genes. RECK expression is reduced in 58.8% of breast cancer tissues and is associated with lymph node invasion supporting its anti-metastatic role. Collectively, we provide the first evidence that RECK can negatively regulate oncogenic activity of HER-2/Neu by inhibiting receptor dimerization.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255571     DOI: 10.1016/j.febslet.2011.01.021

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Reck enables cerebrovascular development by promoting canonical Wnt signaling.

Authors:  Florian Ulrich; Jorge Carretero-Ortega; Javier Menéndez; Carlos Narvaez; Belinda Sun; Eva Lancaster; Valerie Pershad; Sean Trzaska; Evelyn Véliz; Makoto Kamei; Andrew Prendergast; Kameha R Kidd; Kenna M Shaw; Daniel A Castranova; Van N Pham; Brigid D Lo; Benjamin L Martin; David W Raible; Brant M Weinstein; Jesús Torres-Vázquez
Journal:  Development       Date:  2015-12-10       Impact factor: 6.868

2.  RECK impedes DNA repair by inhibiting the erbB/JAB1/Rad51 signaling axis and enhances chemosensitivity of breast cancer cells.

Authors:  Kun-Jing Hong; Ming-Chuan Hsu; Wen-Chun Hung
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

3.  Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer.

Authors:  Kamdeo K Pramanik; Abhay K Singh; Manzar Alam; Tanushree Kashyap; Prajna Mishra; Aditya K Panda; Ratan K Dey; Ajay Rana; Siddavaram Nagini; Rajakishore Mishra
Journal:  Tumour Biol       Date:  2016-09-30

4.  Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.

Authors:  Majid Momeny; Jodi M Saunus; Flavia Marturana; Amy E McCart Reed; Debra Black; Gianluca Sala; Stefano Iacobelli; Jane D Holland; Dihua Yu; Leonard Da Silva; Peter T Simpson; Kum Kum Khanna; Georgia Chenevix-Trench; Sunil R Lakhani
Journal:  Oncotarget       Date:  2015-02-28

5.  Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract.

Authors:  Kiichiro Teruya; Yoshihiro Kusumoto; Hiroshi Eto; Noboru Nakamichi; Sanetaka Shirahata
Journal:  Mar Drugs       Date:  2019-07-19       Impact factor: 5.118

6.  RECK is not an independent prognostic marker for breast cancer.

Authors:  Luciana R Gomes; André Fujita; Joni D Mott; Fernando A Soares; Leticia Labriola; Mari C Sogayar
Journal:  BMC Cancer       Date:  2015-10-08       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.